Feasibility of tumor-informed circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment in pediatric patients with solid tumors. Survival outcomes in patients with high-risk ...

Throughout 2025, Counterpart released three new retrospective data analyses validating CA’s ability to help improve chronic disease management. These studies use real-world data to quantify how CA ...

Medable is bringing generative AI into its clinical trial platform in hopes that the tech will reduce the burden of repetitive tasks on trial sponsors, the company announced in a Nov. 12 release.

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has demonstrated that it can predict the outcome of Phase II to Phase III ...